|Datasheet||Specific References||Reviews||Related Products||Protocols|
pMD18-T Simple Vector is a high-efficiency TA cloning vector constructed from pUC18, of which the initial multiple cloning sites (MCS) were destroyed. Thus the cDNA should be amplified by PCR with primers containing a restriction site for subclone. Competent cells appropriate for pUC18 are also appropriated for the Vector, e.g. JM109, DH5α, TOP10. The pMD18-T Simple Vector is 2.6kb in size. Selection of the plasmid in E. coli is conferred by the ampicillin resistance gene. The coding sequence was inserted by TA cloning at site 425.
The coding sequence can be amplified by PCR with M13-47 and RV-M primers.
|Rat EPO ORF mammalian expression plasmid, C-GFPSpark tag||RG80055-ACG|
|Rat EPO ORF mammalian expression plasmid, C-OFPSpark / RFP tag||RG80055-ACR|
|Rat EPO ORF mammalian expression plasmid, C-Flag tag||RG80055-CF|
|Rat EPO ORF mammalian expression plasmid, C-His tag||RG80055-CH|
|Rat EPO ORF mammalian expression plasmid, C-Myc tag||RG80055-CM|
|Rat EPO ORF mammalian expression plasmid, C-HA tag||RG80055-CY|
|Rat EPO ORF mammalian expression plasmid, N-Flag tag||RG80055-NF|
|Rat EPO ORF mammalian expression plasmid, N-His tag||RG80055-NH|
|Rat EPO ORF mammalian expression plasmid, N-Myc tag||RG80055-NM|
|Rat EPO ORF mammalian expression plasmid, N-HA tag||RG80055-NY|
|Rat EPO natural ORF mammalian expression plasmid||RG80055-UT|
|Learn more about expression Vectors|
Erythropoietin is a member of the EPO / TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. Erythropoietin can be found in the plasma and regulates red cell production by promoting erythroid differentiation and initiating hemoglobin synthesis. It also has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. Erythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. It has a longer circulating half-life in vivo. Erythropoietin is being much misused as a performance-enhancing drug in endurance athletes.